B-cell depleting therapy
- Health
Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency
LACHEN, Switzerland: Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga® in…
Read More »